Publications - Companion/Complementary Diagnostics

Monitoring PD-L1 Expression on Circulating Tumor–Associated Cells in Recurrent Metastatic Non–Small-Cell Lung Carcinoma Predicts Response to Immunotherapy With Radiation Therapy.
Jillian A. Moran, BA; Daniel L. Adams, BS; Martin J. Edelman, MD; Pablo Lopez, PhD; Jianzhong He, PhD; Yawei Qiao, PhD;
Ting Xu, PhD; Zhongxing Liao, PhD; Kirby P. Gardner, MBS; Cha-Mei Tang, ScD; and Steven H. Lin, MD, PhD
2022 American Society of Clinical Oncology
Clinical Applications of Cancer-Associated Cells Present in the Blood of Cancer Patients.
Cha-Mei Tang and Daniel L. Adam.
Biomedicines 2022, 10, 587.
Blood-based biopsies – Clinical Utility beyond circulating tumor cells.
Tang CM, Zhu P, Li S, Makarova OV, Amstutz PT, Adams DL.
Cytometry Part A, first published: 19 October 2018. DOI: 10.1002/cyto.a.23573
Sequential tracking of PD-L1 expression and RAD50 induction in circulating tumor and stromal cells of lung cancer patients undergoing radiotherapy.
Adams DL, Adams DK, He J, Kalhor N, Zhang M, Xu T, Gao H, Reuben JM, Qiao Y, Komaki R, Liao Z, Edelman MJ, Tang C-M, Lin SH,
Clinical Cancer Research, Published OnlineFirst August 16, 2017 DOI: 10.1158/1078-0432.CCR-17-0802
1st International Conference on Polyploid Giant Cancer Cells: Biology and Clinical Application 2024: PD-L1 Expression on Circulating Tumor Associated Macrophage Polyploids Predicts Patient Outcomes in Metastatic Breast Cancer
Immunology 2023 Poster: PD-L1 expression on circulating antigen presenting macrophages in blood predicts PFS & OS in an array of metastatic cancer types treated with PD-L1/PD-1 immunotherapies